T2 Biosystems Inc
Change company Symbol lookup
Select an option...
TTOO T2 Biosystems Inc
BAC Bank of America Corp
DXYN Dixie Group Inc
HEAR Turtle Beach Corp
GWPH GW Pharmaceuticals PLC
GTBIF Green Thumb Industries Inc
GOOG Alphabet Inc
GILD Gilead Sciences Inc
GBLX GB Sciences Inc
FANG Diamondback Energy Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.

Price
Delayed
$0.60
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 180,692 shares is on pace to be much lighter than TTOO's 10-day average volume of 30,358,225 shares.

180,692

TTOO's position in the Biotechnology industry

Industry PeersTTOOOPGN

Summary

Company ProfileT2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform...
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to...
Go to OPGN summary
52-Week Change

VS. INDUSTRY
-77.27%
-80.56%
Market Cap

VS. INDUSTRY
$60.5M
$28.5M
Beta

VS. INDUSTRY
1.2
-0.6
Dividend Yield

VS. INDUSTRY
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$8.3M
$3.5M
Profit Margin

VS. INDUSTRY
-707.93%
-355.75%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
Revenue Growth (TTM)

VS. INDUSTRY
-20.62%
18.75%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.